Skip to main content

Advertisement

SpringerLink
Log in

Predictors of Completion Axillary Lymph Node Dissection in Patients with Positive Sentinel Lymph Nodes

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Completion axillary lymph node dissection (CALND) is routinely performed in breast cancer patients with positive sentinel lymph nodes (SLN). We sought to determine the sociodemographic, pathologic, and therapeutic variables that were associated with CALND.

Methods

From 7/1997 to 7/2003, 1,470 patients with invasive breast cancer were SLN positive by intraoperative frozen section or final pathologic exam by hematoxylin–eosin and/or immunohistochemistry (IHC). A comorbidity score was assigned using Adult Comorbidity Evaluation-27 system. Fisher’s exact, Wilcoxon tests, and multivariate logistic regression analysis were used.

Results

CALND was performed less often in patients with age ≥ 70 years compared with age < 70 years, moderate or severe comorbidities compared with no or mild, IHC-only positive SLN and breast conservation therapy (BCT compared with mastectomy. Patients who did not undergo CALND were less likely than CALND patients to have grade III disease, lymphovascular invasion multifocal disease, tumor size > 2 cm or to receive adjuvant chemotherapy. However, they were more likely to undergo axillary radiotherapy (RT). On multivariate analysis, age ≥ 70 years [odds ratio (OR) 0.4, 95% confidence interval (CI) 0.26–0.63], IHC-only positive SLN (OR 0.13, 95%CI 0.09–0.19), presence of moderate to severe comorbidities (OR 0.64, 95%CI 0.41–0.99), tumor size ≤ 2 cm (OR 0.44, 95%CI 0.29–0.66), axillary RT (OR 0.39, 95%CI 0.20–0.78), and BCT (OR 0.54, 95%CI 0.37–0.79) were all independently associated with lower odds of CALND.

Conclusions

The decision to perform CALND following positive SLN biopsy was multifactorial. Patient factors were a primary determinant for the use of CALND in our study. The decreased use of CALND in the BCT patients probably reflects reliance on the radiotherapy tangents to maintain local control in the axilla.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tan LK, Giri D, Hummer AJ, et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol. 2008;26:1803–9.

    Article  PubMed  Google Scholar 

  2. Bear HD. Completion axillary lymph node dissection for breast cancer: immediate versus delayed versus none. J Clin Oncol. 2008;26:3483–4.

    Article  PubMed  Google Scholar 

  3. Krag DN, Julian TB, Harlow SP, et al. NSABP-32: phase III, randomized trial comparing axillary resection with sentinel lymph node dissection: a description of the trial. Ann Surg Oncol. 2004;11:208S–10.

    PubMed  Google Scholar 

  4. Chu KU, Turner RR, Hansen NM, et al. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg. 1999;229:536–41.

    Article  PubMed  CAS  Google Scholar 

  5. Chu KU, Turner RR, Hansen NM, et al. Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis. Ann Surg Oncol. 1999;6:756–61.

    Article  PubMed  CAS  Google Scholar 

  6. Grube BJ, Giuliano AE. Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ACOSOG Z0011 trial. Semin Surg Oncol. 2001;20:230–7.

    Article  PubMed  CAS  Google Scholar 

  7. Park J, Fey JV, Naik AM, et al. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg. 2007;245:462–8.

    Article  PubMed  Google Scholar 

  8. Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441–7.

    Article  PubMed  CAS  Google Scholar 

  9. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394–399; discussion 399–401.

    Google Scholar 

  10. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–398; discussion 398–401.

    Google Scholar 

  11. Burak WE, Hollenbeck ST, Zervos EE, et al. Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg. 2002;183:23–27.

    Article  PubMed  Google Scholar 

  12. Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95:279–93.

    Article  PubMed  Google Scholar 

  13. Graversen HP, Blichert-Toft M, Andersen JA, et al. Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol. 1988;14:407–12.

    PubMed  CAS  Google Scholar 

  14. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–20.

    Article  PubMed  Google Scholar 

  15. Abdessalam SF, Zervos EE, Prasad M, et al. Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg. 2001;182:316–20.

    Article  PubMed  CAS  Google Scholar 

  16. Degnim AC, Griffith KA, Sabel MS, et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer. 2003;98:2307–15.

    Article  PubMed  Google Scholar 

  17. Kamath VJ, Giuliano R, Dauway EL, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg. 2001;136:688–92.

    Article  PubMed  CAS  Google Scholar 

  18. Turner RR, Chu KU, Qi K, et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 2000;89(3):574–81.

    Article  PubMed  CAS  Google Scholar 

  19. Weiser MR, Montgomery LL, Tan LK, et al. Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes. Ann Surg Oncol. 2001;8:145–9.

    Article  PubMed  CAS  Google Scholar 

  20. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group trial Z0011. J Clin Oncol. 2007;25:3657–63.

    Article  PubMed  Google Scholar 

  21. Furukawa T, Kubota T, Tanino H, et al. Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Anticancer Res. 2000;20:3657–8.

    PubMed  CAS  Google Scholar 

  22. Singletary SE. Systemic treatment after sentinel lymph node biopsy in breast cancer: who, what, and why? J Am Coll Surg. 2001;192:220–30.

    Article  PubMed  CAS  Google Scholar 

  23. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483–93.

    PubMed  CAS  Google Scholar 

  24. Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140–51.

    Article  PubMed  Google Scholar 

  25. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–7.

    Article  PubMed  CAS  Google Scholar 

  26. Hurria A, Leung D, Trainor K, et al. Factors influencing treatment patterns of breast cancer patients age 75 and older. Crit Rev Oncol Hematol. 2003;46:121–6.

    Article  PubMed  Google Scholar 

  27. International Breast Cancer Study G. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group trial 10–93. J Clin Oncol. 2006;24:337–44.

    Article  Google Scholar 

  28. Engel J, Kerr J, Schlesinger-Raab A, et al. Axilla surgery severely affects quality of life: results of a 5-year prospective study in breast cancer patients. Breast Cancer Res Treat. 2003;79:47–57.

    Article  PubMed  Google Scholar 

  29. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival—a Bayesian meta-analysis. Ann Surg Oncol. 1999;6:109–16.

    Article  PubMed  CAS  Google Scholar 

  30. Schlembach PJ, Buchholz TA, Ross MI, et al. Relationship of sentinel and axillary level I–II lymph nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys. 2001;51:671–8.

    PubMed  CAS  Google Scholar 

  31. Pejavar S, Wilson LD, Haffty BG. Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS + RT). Int J Radiat Oncol Biol Phys. 2006;66:1320–7.

    PubMed  Google Scholar 

  32. Gadd M, Harris J, Taghian A, et al. Prospective study of axillary radiation without axillary dissection for breast cancer patients with a positive sentinel node. San Antonio Breast Cancer Symposium Conference Paper December 8–11, 2005. 2005; Abstract 22.

  33. European Organization for Research and Treatment of Cancer. EORTC-10981/AMAROS: after mapping of the axilla: radiotherapy or surgery. A phase III randomized study of complete axillary lymph node dissection versus axillary radiotherapy in sentinel lymph node-positive women with operable invasive breast cancer. http://www.cancer.gov/clinicaltrials/EORTC-10981. Accessed 22 Aug 2008.

  34. Hurkmans CW, Borger JH, Rutgers EJ, et al. Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run. Radiother Oncol. 2003;68:233–40.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Amer K. Karam MD, Meier Hsu MS, Michelle Stempel MS, Hiram S. Cody MD, Elisa R. Port MD, Monica Morrow MD & Mary L. Gemignani MD, MPH

  2. Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Sujata Patil PhD

  3. Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Tiffany A. Traina MD

  4. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Alice Y. Ho MD

Authors
  1. Amer K. Karam MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meier Hsu MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sujata Patil PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michelle Stempel MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tiffany A. Traina MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alice Y. Ho MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiram S. Cody MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Elisa R. Port MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Monica Morrow MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mary L. Gemignani MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary L. Gemignani MD, MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karam, A.K., Hsu, M., Patil, S. et al. Predictors of Completion Axillary Lymph Node Dissection in Patients with Positive Sentinel Lymph Nodes. Ann Surg Oncol 16, 1952–1958 (2009). https://doi.org/10.1245/s10434-009-0440-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0440-6

Keywords

Search

Navigation